NATCO PHARMA

NATCO PHARMA CMP @ 147.95

INVESTMENT PICK :) PURE FUNDA PICK @ SAJAN :)

SAJAN IS A WHOLESALE DISTRIBUTOR OF MEDICINES AT PUNJAB .. SO WHT BETTER HE CAN PICK OTHER THEN A PHARMA STOCK

This Funda report is based on research done by Sajan @ this stock... this report is not a work of copy paste from any other research reports and i am 5000 % sure after this people will give there views @ natco like they discovered it :) WEL DONE SAJAN :) WE KNOW U DISCOVERED IT :)

Natco made many drugs for cancer amd cheapest from rest of the companies.

Continuing with its stated objective of providing qualitative medicare at affordable prices, the Company is making available Pemnat at an MRP of Rs 25,500 per vial, as against the imported medicine costing around Rs 79,000. Incidentally this would be the first launch of Pemetrexed generic version in the World. Being a pre-1995 invention, the Company does not expect any litigation over the generic launch. and no competetion

Pemnat (Pemetrexed) for treatment of non-small cell lung cancer

Having already achieved leadership position from among the Indian companies in the oncology segment, the Company expects to further improve its revenues with this launch.

Akorn, USA EVER HEARD OF THIS CO. ? Its Stock doubled from 3 $ to 6$ ???

Natco Pharma Ltd has announced a tie-up with USA based Akorn, Inc. for API Supply and Margin Sharing to commercialize two ANDA injectable drug products.
The two ANDA drug products will focus on the anti-emetic and cancer related markets, and have a combined current market size of approximately $ 875 million. Under the API Supply and Margin Sharing Agreement, the Company will be responsible for the supply of active pharmaceutical ingredients for both drug products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home healthcare markets in the United States and Canada.

Natco Pharma Ltd has announced addition of two injectable drug products to its existing API Supply and Margin Sharing Agreement with Akorn Inc., USA. With this agreement, the total number of products covered under the agreement goes up to four.
The two ANDA drug products are indicated for the prevention of nausea and vomiting associated with cancer chemotherapy, and have a combined current market size of approximately $360 million. Under the API Supply and Margin Sharing Agreement that was signed in April 2006, the Company will be responsible for the supply of active pharmaceutical ingredients for both drug products, while Akorn will be responsible for the manufacturing, regulatory submissions, marke

Bortenat at Rs 16,800 MRP as against Rs 75,000 of the imported medicine. Being a pre 1995 invention, the Company does not expect any litigation around this molecule.

Whats Bortenat ???
Bortenat (Bortezomib) is used in the treatment of multiple myeloma.

Natco Pharma Ltd has announced the launch of its brand — Bortenat (Bortezomib) 3.5 mg. injection.

Natco Pharma Ltd has announced the launch of its brand Lymfuda 10 mg tablets. Lymfuda (Fludarabine), is an alkylating agent, useful in the treatment of chronic lymphocytic leukemia (CLL). Launched for the first time in India, Lymfuda will substitute imports and is competitively priced at around 60% of the cost of the imported medicine.

Superior to Zoledronic acid, use of Ibandronate avoids monitoring of kidney function prior to each infusion and dose adjustments in patients with mild to moderate impairment.
A first time launch in India, this drug is competitively priced at Rs 2500/- per 6 mg injection and at Rs 49/- per 50 mg tablet, against the price of imported versions of Rs 13,500/- per injection and Rs 600/- per tablet.


LAND = 350 acr @ hyderabad

AND IN WHOLE MARKET CRASH IT DIDNT MOVED DOWN WHERE AS ALL PHARMA STOCKS WERE BEING THRASHED :)

SHAREHOLDING
AS ON DEC 06
Promoter and Promoter Group = 62.23 %

FII and FI's =

1 Jerymyn Capital LLC 3.53
2 Citigroup Global Markets Mauritius Pvt Ltd 1.72
3 Goldman Sachs Investments Mauritius 5.05
4 Morgan Stanley & Co. International Ltd 2.01
Total 12.32

Promoter + FII + FI = 62.23+12.32=74.56%

TEHNICALS

SUPP @ 142.50-138-130
RES @ 150-54-60

BREAKOUT ^ 160

LET IT BREAKOUT THEN WE WOUDL UPDATE THE NEXT LEVELS:)